A 43-year-old woman with well-controlled HIV was prescribed a 6-month course of isoniazid preventative therapy (IPT) (300 mg daily) and pyridoxine (50 mg daily) for latent tuberculosis as part of a nationwide effort in Uganda to decrease the burden of tuberculosis among persons with HIV \[[@bib0005]\]. Approximately 4 months later, she developed symmetric, photo-distributed, well-demarcated, severely pruritic plaques with scale resembling peeling paint on her bilateral forearms, posterior neck, and upper back ([Fig. 1](#fig0005){ref-type="fig"}). She denied gastrointestinal or neurologic symptoms. Before visiting the dermatology clinic, the working diagnosis of her primary provider was allergic contact dermatitis, but she remained untreated.Fig. 1Well-demarcated plaques with "peeling paint" scale distributed symmetrically on sun-exposed sites.Fig. 1

Based on the morphology, distribution, and developmental time course of her rash, a clinical diagnosis of isoniazid-related pellagra was made. Given the high cost of niacin locally, a twice-daily B complex multivitamin containing 7.5 mg niacinamide was prescribed. Topical betamethasone ointment twice daily was given for pruritus. Her IPT was also stopped, as she had received five of six months of the planned course. One month later, her rash had completely resolved, leaving behind post-inflammatory hyperpigmentation and mild, steadily improving residual pruritus.

Pellagra is a clinical syndrome caused by vitamin B3 (niacin) deficiency. Although classically associated with altered vitamin B6 (pyridoxine) metabolism, isoniazid also interferes indirectly with the conversion of tryptophan to nicotinamide \[[@bib0010]\]. Isoniazid may therefore cause pellagra despite pyridoxine supplementation. This is especially relevant in settings where maize is the staple dietary carbohydrate for the population \[[@bib0015]\]. If available, clinicians practicing in such areas should consider obtaining baseline tryptophan and nicotinamide serum levels and initiating B complex vitamin and/or nicotinamide supplementation at the onset of IPT.

In settings planning broad IPT implementation, patients should be educated about possible adverse effects of isoniazid, and physicians should be comfortable recognizing and treating these, including pellagra. Isoniazid-related pellagra usually resolves after the offending medication is stopped. For patients that must continue IPT, nicotinamide or a B complex multivitamin, in addition to dietary counseling regarding niacin-rich food sources (including beef liver, chicken breast, marinara sauce, tuna fish, brown rice, and peanuts) \[[@bib0020]\], are appropriate initial steps. Medium- to high-potency topical corticosteroid ointment can help relieve symptoms while the underlying cause is being addressed. For those with severe symptoms refractory to these measures, physicians should consider premature termination of IPT followed by careful monitoring for signs of active TB. Alternative regimens such as rifampin, which is associated with greater completion rates and less hepatotoxicity compared to isoniazid \[[@bib0025]\], should also be considered.
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